Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on January 10, 2008

Arteriosclerosis, Thrombosis, and Vascular Biology. 2008
Published online before print January 10, 2008, doi: 10.1161/ATVBAHA.107.160432
A more recent version of this article appeared on March 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Additional Materials
Right arrow All Versions of this Article:
28/3/478    most recent
ATVBAHA.107.160432v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kern, J.
Right arrow Articles by Untergasser, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kern, J.
Right arrow Articles by Untergasser, G.

Submitted on May 15, 2007
Accepted on December 20, 2007

Alternative Splicing of Vasohibin-1 Generates an Inhibitor of Endothelial Cell Proliferation, Migration, and Capillary Tube Formation

Johann Kern ; Monika Bauer ; Kathrin Rychli ; Johann Wojta ; Andreas Ritsch ; Günther Gastl ; Eberhard Gunsilius ; and Gerold Untergasser *

From the Tumor Biology & Angiogenesis Laboratory (J.K., M.B., G.G., E.G., G.U.), Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck; the Department of Internal Medicine II (K.R., J.W.), Medical University of Vienna; and the Gene Therapy Group (A.R.), Division of General Internal Medicine, Innsbruck Medical University, Innsbruck, Austria.

* To whom correspondence should be addressed. E-mail: gerold.untergasser{at}i-med.ac.at.

Objective—In this study, the alternative splicing product of vasohibin 1 (VASH1B) was analyzed in direct comparison to the major isoform (VASH1A) for antiangiogenic effects on endothelial colony forming cells (ECFCs) from peripheral blood and on human umbilical vein endothelial cells (HUVECs).

Methods and Results—Expression studies in primary human endothelial cells revealed that both vasohibin proteins, hVASH1A and hVASH1B, localized in the nucleus and cytoplasm. Adenoviruses carrying the cDNA for VASH1A/B and purified recombinant proteins were used to study the function of both molecules in ECFCs and HUVECs. Recombinant VASH1A protein did not inhibit cell proliferation, tube formation, or vessel growth in vivo in the chick chorioallantoic membrane (CAM) assay, but promoted endothelial cell migration in vitro. The VASH1B protein had an inhibitory effect on cell proliferation, migration, tube formation, and inhibited blood vessel formation in the CAM assay. Adenoviral overexpression of VASH1B, but not of VASH1A, resulted in inhibition of endothelial cell growth, migration, and capillary formation. Interestingly, overexpression of VASH1A and B induced apoptosis in proliferating human fibroblasts, but did not affect cell growth of keratinocytes.

Conclusion—Our data point out that alternative splicing of the VASH1 pre-mRNA transcript generates a potent antiangiogenic protein.


Key words: adenovirus • endothelial cells • vasohibin • alternative splicing